Scientists Harness AI to Create Nasal Antivirals for Flu and COVID-19

Researchers have made significant strides in antiviral treatments using artificial intelligence (AI), developing nasal sprays designed to prevent infections from viruses like influenza and COVID-19. This novel approach shifts the focus from treating infections once they have established themselves to blocking them at the earliest point of entry into the body.

AI-Driven Innovations in Antiviral Development

One notable advancement comes from Washington State University, where scientists employed AI and molecular simulations to pinpoint a critical interaction necessary for viral entry. Detailed findings, published in the journal Nanoscale, highlighted how the team analyzed a fusion protein utilized by herpes viruses to invade cells. By examining thousands of amino acid interactions, the AI model identified a specific interaction vital for the virus to fuse with host cells.

Once researchers modified this interaction in laboratory tests, the virus was unable to enter the cells. Lead researcher Jin Liu stated that the use of AI significantly expedited the discovery process, eliminating the need for extensive trial and error. While this research focused on herpes viruses, its implications extend to respiratory viruses, suggesting a potential for broader antiviral strategies.

Another breakthrough emerged from KAIST, where a team has engineered a nasal antiviral platform aimed at effectively blocking rapidly mutating respiratory viruses. According to coverage from MedicalXpress, researchers redesigned interferon-lambda, a natural immune protein, enhancing its stability and effectiveness within the nasal cavity. Interferon-lambda is crucial in inhibiting viral replication, but previous formulations struggled due to degradation caused by heat, enzymes, and mucus.

Through AI-driven protein design, the team fortified weak structural areas and altered the protein’s surface to enhance stability and prevent clumping. The newly designed protein was combined with advanced delivery methods, including encapsulation in nanoliposomes, which ensured the antiviral adhered to the nasal lining for extended periods, thereby boosting its protective capabilities.

Promising Results and Future Implications

In animal studies involving influenza, the AI-enhanced nasal spray demonstrated a remarkable reduction of more than 85 percent in viral levels within the nasal cavity. Additionally, the treatment maintained stability at elevated temperatures and effectively penetrated thick mucus. These characteristics make the platform particularly viable for use in real-world scenarios.

A nasal spray that does not require stringent cold storage could be rapidly deployed during outbreaks, especially in areas with limited healthcare infrastructure. Researchers believe that this platform could be adapted for COVID-19 and other future respiratory threats, particularly those that evolve quickly and evade existing vaccines.

These studies underscore a growing trend in antiviral research that emphasizes targeting universal mechanisms, such as viral cell entry and early immune responses, rather than merely chasing evolving viral strains. By preventing viruses from establishing an infection, nasal antivirals could serve as a vital complement to traditional vaccines. While vaccines prepare the immune system over time, nasal sprays could provide immediate, localized protection during periods of elevated exposure.

Despite these promising developments, researchers caution that further testing is necessary before human application. Clinical trials will be essential to confirm safety, optimal dosage, and effectiveness across various viral strains. Nevertheless, the integration of AI in the discovery and design process represents a critical shift in antiviral research. As these tools advance, they may enable scientists to respond more swiftly to emerging viral threats and reduce reliance on conventional reactive treatments.

The findings suggest a future where preventing infections could be as straightforward as a nasal spray applied before viruses gain a foothold, potentially transforming public health responses to viral outbreaks.